Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine
Advanced Science · 2025-05 · 12 (19)
DOI: 10.1002/advs.202500021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.03.2025. Verfasst von Yu Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Liposomes, Spleen, Cancer Vaccines, Antigen-Presenting Cells. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Xisike Clinical Oncology Research Foundation, Science and Technology Program of Guangzhou.
Abstract (Originalsprache)
Effective immune responses in both the spleen and the tumor microenvironment are crucial for cancer immunotherapy. However, delivery of neoantigen peptide vaccines to antigen‐presenting cells (APCs) at these sites remains challenging. In this study, LNPs D18 , a cationic liposomal formulation that targets and enhances APC uptake at both sites without modifying the targeting ligands is developed. By co‐delivering tumor‐specific neoantigens and a cholesterol‐coupled toll‐like receptor 9 (TLR9) agonist within LNP‐vax D18 , an approximately 60‐fold increase in dendritic cell uptake compared to neoantigen‐adjuvant mixtures is achieved. Intravenous administration of the liposome‐neoantigen peptide vaccine targets both the spleen and the tumor, boosting splenic DC activation, increasing M1‐type tumor‐associated macrophages, and elevating tumor cytokine levels. This reshapes the tumor microenvironment, enhancing IFN‐γ‐producing CD8 + T cells and TCF1 + CD8 + T cells within tumors. These outcomes significantly inhibit established tumor growth compared to nontargeted lipid‐based nanovaccine formulations, resulting in improved survival in orthotopic hepatocellular carcinoma and colorectal cancer models. The findings highlight the importance of targeting APCs in both the spleen and tumors to optimize the therapeutic efficacy of liposome‐neoantigen vaccines in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, P. R…
- Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, 510060, P. R. China.
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, P. R. China.
- Fujian Agriculture and Forestry University, Fuzhou, 350002, P. R. China.
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
- Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, P. R. China.
ORCID-Profile: Da Zhang, Xiaolong Liu, Feng Wang
Förderung
- National Natural Science Foundation of China
- Beijing Xisike Clinical Oncology Research Foundation
- Science and Technology Program of Guangzhou
- Young Talents Program of Sun Yat-sen University Cancer Center
- Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
- Fujian Province Outstanding Youth Science Fund Projects
- Fujian Provincial Health and Middle-aged and Young Scientific Research Major Projects
- Fujian Provincial Health and Medical Innovation Project
Zitieren
APA
Xu, Y., Wang, B., Huang, Y., Liao, J., Wu, C., Zhou, C., Kang, Z., Jiang, S., Wu, B. C., Zhang, D., Xu, R., Liu, X., & Wang, F. (2025). Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine. Advanced Science, 12(19). https://doi.org/10.1002/advs.202500021
Vancouver
Xu Y, Wang B, Huang Y, Liao J, Wu C, Zhou C, et al. Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine. Advanced Science. 2025;12(19). doi:10.1002/advs.202500021
BibTeX
@article{Xu2025,
author = {Xu, Yu and Wang, Bing and Huang, Yue and Liao, JianPing and Wu, Chenyi and Zhou, Chenxi and Kang, Zishi and Jiang, Shiyang and Wu, Bing-Chen and Zhang, Da and Xu, Ruihua and Liu, Xiaolong and Wang, Feng},
title = {Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {19},
doi = {10.1002/advs.202500021}
}
EUVIMED